Platelet activation and endothelial dysfunction biomarkers in acute coronary syndrome: the impact of PCSK9 inhibition.

Efthymios ZiogosStephen P ChelkoTarek HarbMorgan EngelMichael A VavuranakisMaicon Landim-VieiraElise M WalshShenghan LaiMarc K HalushkaGary GerstenblithThorsten M Leucker

Published in: European heart journal. Cardiovascular pharmacotherapy (2023)

PCSK9 inhibition decreases markers of platelet activation and endothelial dysfunction in ACS patients. PCSK9 is associated with platelets and vascular ECs in LIMA segments and PCSK9 inhibition decreases that interaction.

Keyphrases

acute coronary syndrome
low density lipoprotein
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
antiplatelet therapy
prognostic factors